NCT03108027View on ClinicalTrials.gov

Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

February 24, 2018

Study Completion Date

February 24, 2018

Conditions
Asthma
Interventions
DRUG

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

DRUG

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

DRUG

Treatment C: Placebo (morning dose) and placebo (evening dose)

Placebo (morning dose) and placebo (evening dose)

Trial Locations (7)

9713

Novartis Investigative Site, Groningen

10117

Novartis Investigative Site, Berlin

22947

Novartis Investigative Site, Großhansdorf

30625

Novartis Investigative Site, Hanover

60596

Novartis Investigative Site, Frankfurt Am Main Hessen

65187

Novartis Investigative Site, Wiesbaden

M23 9QZ

Novartis Investigative Site, Machester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY